Congress Asset Management Co. Sells 429,504 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Congress Asset Management Co. decreased its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 99.0% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 4,361 shares of the medical research company's stock after selling 429,504 shares during the quarter. Congress Asset Management Co.'s holdings in Charles River Laboratories International were worth $805,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Versant Capital Management Inc lifted its holdings in shares of Charles River Laboratories International by 1,071.4% in the fourth quarter. Versant Capital Management Inc now owns 164 shares of the medical research company's stock worth $30,000 after buying an additional 150 shares in the last quarter. Pinnacle Bancorp Inc. boosted its holdings in Charles River Laboratories International by 52.0% in the 4th quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company's stock valued at $35,000 after purchasing an additional 65 shares during the period. Assetmark Inc. grew its position in shares of Charles River Laboratories International by 1,153.3% during the 3rd quarter. Assetmark Inc. now owns 188 shares of the medical research company's stock valued at $37,000 after purchasing an additional 173 shares in the last quarter. ORG Wealth Partners LLC purchased a new stake in shares of Charles River Laboratories International in the fourth quarter worth $56,000. Finally, Wilmington Savings Fund Society FSB bought a new stake in Charles River Laboratories International during the third quarter valued at $59,000. Institutional investors own 98.91% of the company's stock.

Analyst Upgrades and Downgrades

CRL has been the topic of several recent analyst reports. Morgan Stanley lowered their price target on Charles River Laboratories International from $220.00 to $184.00 and set an "equal weight" rating on the stock in a report on Wednesday, February 5th. TD Cowen lifted their target price on shares of Charles River Laboratories International from $203.00 to $227.00 and gave the company a "hold" rating in a research report on Monday, November 11th. Robert W. Baird dropped their target price on shares of Charles River Laboratories International from $177.00 to $173.00 and set a "neutral" rating for the company in a research report on Thursday. William Blair lowered shares of Charles River Laboratories International from an "outperform" rating to a "market perform" rating in a research report on Wednesday, January 22nd. Finally, Bank of America dropped their target price on shares of Charles River Laboratories International from $220.00 to $210.00 and set a "neutral" rating for the company in a research report on Friday, December 13th. Three research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating and one has issued a buy rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and an average target price of $195.71.

Insider Transactions at Charles River Laboratories International

In other Charles River Laboratories International news, CEO James C. Foster bought 6,075 shares of Charles River Laboratories International stock in a transaction dated Thursday, February 20th. The shares were purchased at an average cost of $165.01 per share, with a total value of $1,002,435.75. Following the transaction, the chief executive officer now directly owns 183,639 shares of the company's stock, valued at $30,302,271.39. This represents a 3.42 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Joseph W. Laplume sold 4,400 shares of the company's stock in a transaction dated Thursday, February 20th. The stock was sold at an average price of $162.50, for a total transaction of $715,000.00. Following the completion of the transaction, the executive vice president now owns 20,013 shares in the company, valued at approximately $3,252,112.50. The trade was a 18.02 % decrease in their position. The disclosure for this sale can be found here. Insiders own 1.30% of the company's stock.

Charles River Laboratories International Trading Up 0.5 %

Shares of NYSE CRL traded up $0.86 during mid-day trading on Friday, hitting $163.11. The stock had a trading volume of 1,215,947 shares, compared to its average volume of 1,060,465. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.14 and a current ratio of 1.41. Charles River Laboratories International, Inc. has a 1 year low of $150.79 and a 1 year high of $275.00. The business has a 50 day moving average price of $173.39 and a two-hundred day moving average price of $188.81. The firm has a market cap of $8.34 billion, a P/E ratio of 1,087.39, a price-to-earnings-growth ratio of 6.77 and a beta of 1.37.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last issued its earnings results on Wednesday, February 19th. The medical research company reported $2.66 EPS for the quarter, topping the consensus estimate of $2.50 by $0.16. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The company had revenue of $1 billion for the quarter, compared to the consensus estimate of $983.63 million. During the same period in the previous year, the firm earned $2.46 earnings per share. The firm's revenue for the quarter was down 1.1% on a year-over-year basis. On average, equities analysts anticipate that Charles River Laboratories International, Inc. will post 9.41 EPS for the current fiscal year.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).